ArticleCancer science2026

Refining Tumor Mutational Burden as a Predictive Biomarker for Pembrolizumab: A Real-World Analysis in Japanese Patients.

Tomoyo Yasuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.